[A Case of Dedifferentiated Retroperitoneal Liposarcoma That Survived Long-Term after Eight Surgeries].

The case was a 68-year-old woman who presented with a complaint of an abdominal mass. She was diagnosed with the retroperitoneal liposarcoma. In the initial surgery, the primary tumor was resected together with the right colon involved.

[First-Line Treatment of Advanced ER-Positive HER2-Negative Breast Cancer in Ikeda City Hospital].

In patients with ER-positive HER2-negative unresectable breast cancer, who are refractory to chemotherapy, surgery may not be performed even after endocrine therapy. CDK4/6 inhibitors have been used as first-line treatment for unresectable breast cancer since their approval in Japan. We investigated the primary treatment of ER-positive HER2-negative inoperable breast cancer and its efficacy in our hospital.

Stage III substaging and outcomes in patients with bladder cancer undergoing radical cystectomy.

Objective: To examine the association between substaging and outcomes following radical cystectomy (RC) in patients with stage III bladder cancer.

Methods: We conducted a retrospective observational study using nationwide data from Japan, including 708 patients with stage III bladder cancer who underwent RC. Substaging was based on the American Joint Committee on Cancer's 8th edition.

Therapeutic efficacy of immune-oncology combination therapy in advanced renal cell carcinoma without prior nephrectomy.

Background: Immuno-oncology (IO) combination therapies, including IO + IO or IO + vascular endothelial growth factor targeted therapies (VEGF-TT), have become the standard first-line treatment for advanced renal cell carcinoma (RCC). However, the optimal regimen for patients without prior nephrectomy remains unclear.

Methods: Data from 99 patients with advanced RCC without nephrectomy, treated with VEGF-TT, IO + IO, or IO + VEGF-TT between May 2008 and May 2024, were retrospectively reviewed and analyzed.